All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

RAS family proteins, including HRAS, KRAS, NRAS, RRAS1, RRAS2 (or TC21), RRAS3 (or MRAS) and ERAS, act as signaling nodes and regulate the function of various effectors with divergent biochemical functions in all eukaryotes \[[@pone.0167145.ref001],[@pone.0167145.ref002],[@pone.0167145.ref003]\]. Signal transduction implies physical association of these proteins with a spectrum of functionally diverse downstream effectors, *e*.*g*., CRAF, PI3Kα, RALGDS, PLCε and RASSF5, and their activation \[[@pone.0167145.ref001],[@pone.0167145.ref004],[@pone.0167145.ref005],[@pone.0167145.ref006],[@pone.0167145.ref007],[@pone.0167145.ref008],[@pone.0167145.ref009],[@pone.0167145.ref010]\]. CRAF, a serine/threonine kinase, activates the MEK-ERK axis and controls gene expression and cell proliferation \[[@pone.0167145.ref011]\]. PI3Kα generates phosphatidylinositol (3,4,5)-trisphosphate (PIP~3~) and regulates cell growth, cell survival, cytoskeleton reorganization, and metabolism \[[@pone.0167145.ref012]\]. RALGDS links RAS with RAL, a RAS-related protein, and regulates cellular processes, such as vesicular trafficking and migration \[[@pone.0167145.ref013]\]. PLCε generates two second messengers of diacylglycerol (DAG) and inositol trisphosphate (IP~3~) leading to an intracellular increase of calcium levels, which controls endocytosis, exocytosis, and cytoskeletal reorganization \[[@pone.0167145.ref014]\]. RASSF5 forms a complex with MST1/2 kinases, human orthologues of Hippo, and WW45 which promote apoptosis and cell cycle arrest \[[@pone.0167145.ref015]\].

Gain-of-function RAS mutations are frequently found in human cancers, (*e*.*g*., pancreatic cancer \[[@pone.0167145.ref016]\]) and developmental disorders, including Noonan syndrome \[[@pone.0167145.ref017],[@pone.0167145.ref018],[@pone.0167145.ref019]\]. Whereas the latter is thought to be commonly caused by dysregulation of mainly one pathway, the RAS-MAPK pathway \[[@pone.0167145.ref019]\], RAS-mediated cancer progression involves activation of several pathways, *e*.*g*., PI3K-AKT \[[@pone.0167145.ref003],[@pone.0167145.ref020]\], RALGDS-RAL \[[@pone.0167145.ref009],[@pone.0167145.ref013]\], PLCε-second messengers \[[@pone.0167145.ref014]\] or Hippo-YAP \[[@pone.0167145.ref021]\] as well as RAS-MAPK \[[@pone.0167145.ref022]\]. Understanding how effectors selectively recognize RAS-GTP is an attractive approach to functionalize peptides and peptidomimetics capable of inhibiting RAS interactions and signaling.

RAS effectors contain either a RAS binding (RB) or a RAS association (RA) domain (among other domains; [Fig 1](#pone.0167145.g001){ref-type="fig"}) \[[@pone.0167145.ref007],[@pone.0167145.ref023],[@pone.0167145.ref024]\]. RAS-effector interaction essentially requires RAS association with membranes \[[@pone.0167145.ref025]\] and its activation by specific regulatory proteins (*e*.*g*., guanine nucleotide exchange factors or GEFs), leading to the formation of GTP-bound, active RAS \[[@pone.0167145.ref026],[@pone.0167145.ref027],[@pone.0167145.ref028]\]. Notably, RAS proteins change their conformation mainly at two highly mobile regions, designated as switch I (residues 30--40) and switch II (residues 60--68) \[[@pone.0167145.ref029],[@pone.0167145.ref030]\]. Only in GTP-bound form, the switch regions of the RAS proteins provide a platform for the association with effector proteins, especially through their RB or RA domains, respectively. This interaction appears to be a prerequisite for effector activation \[[@pone.0167145.ref024],[@pone.0167145.ref031],[@pone.0167145.ref032],[@pone.0167145.ref033]\]. RB/RA associations with RAS proteins do not exhibit the same mode of interaction among different RAS effectors \[[@pone.0167145.ref024],[@pone.0167145.ref034],[@pone.0167145.ref035],[@pone.0167145.ref036]\]. However, CRAF-RB and RALGDS-RA domains share a similar ubiquitin-like fold and contact the switch I region *via* a similar binding mode. In contrast, PI3Kα-RB, RASSF5-RA and PLCε-RA domains do not share sequence and structural similarity but commonly associate with the switch regions, especially switch I \[[@pone.0167145.ref034],[@pone.0167145.ref035],[@pone.0167145.ref036],[@pone.0167145.ref037],[@pone.0167145.ref038]\]. Early cell-based studies have shown that distinct amino acids in switch I, *e*.*g*., Thr-35, Glu-37, Asp-38 or Tyr-40) dictate effector specificity \[[@pone.0167145.ref039],[@pone.0167145.ref040],[@pone.0167145.ref041],[@pone.0167145.ref042]\]. However, there is no clear explanation for such a differential selection of the switch I region by various effectors.

![Domain organization of RAS effectors and different proteins used in this study.\
(A) Various domains are highlighted, including RAS association domain (RA) and RAS-binding (RB) domain in blue. The numbers indicate the N- and C-terminal amino acids of the respective effector domain used in this study. Other domains are: C1, cysteine-rich lipid binding; C2, calcium-dependent lipid binding; CRD, cysteine rich domains; DEP, Dishevelled/Egl-10/Pleckstrin; EF, EF-hand; kinase, serine/threonine or phosphoinositide kinase; PH, pleckstrin homology; PI3K, Phosphoinositide 3-kinase family, accessory *domain;* PP, proline-rich region; RA, RAS association; RALGEF, RAL specific guanine nucleotide exchange factor; RASGEF, RAS specific guanine nucleotide exchange factor; RB, RAS binding; REM, RAS exchanger motif; SARAH, Salvador/RASSF/Hippo. (B) Coomassie brilliant blue (CBB) stained SDS-PAGE of purified MBP fusion proteins used in this study.](pone.0167145.g001){#pone.0167145.g001}

To date, various methods and different conditions for measuring the binding affinity between different effectors and RAS proteins, especially HRAS, have been used in many laboratories (reviewed in \[[@pone.0167145.ref004],[@pone.0167145.ref024],[@pone.0167145.ref043]\]), as summarized in [Table 1](#pone.0167145.t001){ref-type="table"}. In this study, the interactions of five different RAS proteins with both the RB domains of CRAF and PI3Kα, and the RA domains of RALGDS, PLCε and RASSF5 were reinvestigated under comparable conditions using fluorescence polarization. In addition, available complex structures and sequence alignments were utilized to construct an interaction matrix and systematically assess the association of investigated effector domains with various RAS proteins. The dissociation constants (K~d~ values) obtained were combined with the interaction matrix enabling us to determine common hotspots as critical specificity-determining residues and to predict selectivity of five RB- and RA-containing proteins.

10.1371/journal.pone.0167145.t001

###### Register of dissociation constants (K~d~) determined for the RAS-effector interactions.

![](pone.0167145.t001){#pone.0167145.t001g}

  RAS             Nnucleotide[^a^](#t001fn001){ref-type="table-fn"}   Effectors[^b^](#t001fn002){ref-type="table-fn"}   K~d~ (μM)   Method[^c^](#t001fn003){ref-type="table-fn"}   T (°C)                       Reference
  --------------- --------------------------------------------------- ------------------------------------------------- ----------- ---------------------------------------------- ---------------------------- ----------------------------
  HRAS            mGTPγS                                              CRAF-RB                                           0.005       GDI                                            37                           \[[@pone.0167145.ref102]\]
  mGDP            CRAF-RB                                             24.0                                              GDI         37                                             \[[@pone.0167145.ref102]\]   
  \[^3^H\]GTP     CRAF-RB                                             0.065                                             SPA         37                                             \[[@pone.0167145.ref103]\]   
  \[γ^32^P\]GTP   CRAF-N275                                           0.029                                             CPA         4                                              \[[@pone.0167145.ref104]\]   
  \[γ^32^P\]GTP   RALSGDS-C127                                        0.028                                             CPA         4                                              \[[@pone.0167145.ref104]\]   
  mGppNHp         AF6-RA1                                             2.4                                               GDI         37                                             \[[@pone.0167145.ref105]\]   
  AF6-RA1         2.4                                                 FK                                                10          \[[@pone.0167145.ref106]\]                                                  
  AF6-RA1         2.8                                                 FK                                                25          \[[@pone.0167145.ref107]\]                                                  
  CRAF-RB         0.16                                                FK                                                25          \[[@pone.0167145.ref107]\]                                                  
  CRAF-RB         0.14                                                FP                                                25          \[[@pone.0167145.ref108]\]                                                  
  CRAF-RB         0.22                                                FP                                                25          \[[@pone.0167145.ref018]\]                                                  
  CRAF-RB         0.018                                               GDI                                               37          \[[@pone.0167145.ref102]\]                                                  
  CRAF-RB         0.16                                                GDI                                               25          \[[@pone.0167145.ref109]\]                                                  
  CRAF-RB         0.33                                                GDI                                               25          \[[@pone.0167145.ref110]\]                                                  
  RALGDS-RA       2.70                                                FP                                                25          \[[@pone.0167145.ref108]\]                                                  
  RALGDS-RA       1.30                                                FK                                                25          \[[@pone.0167145.ref107]\]                                                  
  RALGDS-RA       3.50                                                GDI                                               37          \[[@pone.0167145.ref111]\]                                                  
  RASSF5-RA       5.20                                                FP                                                25          \[[@pone.0167145.ref108]\]                                                  
  RASSF5-RA       0.8                                                 GDI                                               37          \[[@pone.0167145.ref035]\]                                                  
  RASSF5-RA       0.08                                                FK                                                37          \[[@pone.0167145.ref035]\]                                                  
  PLCε-RA2        5.20                                                FP                                                25          \[[@pone.0167145.ref108]\]                                                  
  GppNHp          CRAF-RB                                             0.08                                              ITC         25                                             \[[@pone.0167145.ref112]\]   
  AF6-RA1         3.00                                                ITC                                               25          \[[@pone.0167145.ref112]\]                                                  
  AF6-RA1         2.20                                                ITC                                               25          \[[@pone.0167145.ref024]\]                                                  
  RALGDS-RA       1.0                                                 ITC                                               25          \[[@pone.0167145.ref112]\]                                                  
  RALGDS-RA       1.0                                                 ITC                                               25          \[[@pone.0167145.ref024]\]                                                  
  RASSF1-C1-RA    39.0                                                ITC                                               25          \[[@pone.0167145.ref024]\]                                                  
  RASSF5-C1-RA    0.40                                                ITC                                               25          \[[@pone.0167145.ref113]\]                                                  
  RASSF5-RA       0.21                                                ITC                                               25          \[[@pone.0167145.ref113]\]                                                  
  PLCε-RA2        0.82                                                ITC                                               25          \[[@pone.0167145.ref024]\]                                                  
  PLCε-RA1/2      0.98                                                ITC                                               25          \[[@pone.0167145.ref024]\]                                                  
  AF6-RA1(Y32W)   0.58                                                WF                                                10          \[[@pone.0167145.ref106]\]                                                  
  KRAS            mGppNHp                                             CRAF-RB                                           0.04        GDI                                            37                           \[[@pone.0167145.ref102]\]
  CRAF-RB         0.102                                               ITC                                               25          \[[@pone.0167145.ref017]\]                                                  
  GppNHp          CRAF-RB                                             0.056                                             BBA         25                                             \[[@pone.0167145.ref114]\]   
  NRAS            mGppNHp                                             RAF-RB                                            0.04        GDI                                            37                           \[[@pone.0167145.ref102]\]
  PI3Kγ-RB        2.90                                                FP                                                20          \[[@pone.0167145.ref036]\]                                                  
  RRAS1           mGppNHp                                             CRAF-RB                                           252.9       FP                                             25                           \[[@pone.0167145.ref115]\]
  RALGDS-RA       376.7                                               FP                                                25          \[[@pone.0167145.ref115]\]                                                  
  RASSF5-RA       54.6                                                FP                                                25          \[[@pone.0167145.ref115]\]                                                  
  PLCε-RA1        306.6                                               FP                                                25          \[[@pone.0167145.ref115]\]                                                  
  PI3Kα-RB        330.5                                               FP                                                25          \[[@pone.0167145.ref115]\]                                                  
  CRAF-RB         1.10                                                GDI                                               37          \[[@pone.0167145.ref116]\]                                                  
  RRAS3           GppNHp                                              AF6-RA1                                           2.80        ITC                                            25                           \[[@pone.0167145.ref024]\]
  RALGDS-RA       3.70                                                ITC                                               25          \[[@pone.0167145.ref024]\]                                                  
  PLCε-RA1/2      7.50                                                ITC                                               25          \[[@pone.0167145.ref024]\]                                                  

^a^ Different GTP or GDP analogs bound to HRAS have been used: GppNHp, Guanosine-5\'- \[(β,γ) -imido\]triphosphate; mGDP, N-methylanthraniloyl-guanosine-5\'-diphosphate; mGppNHp, N-methylanthraniloyl-GppNHp; mGTPγS, N-methylanthraniloyl-guanosine 5\'-\[gamma-thio-\]triphosphate; \[^3^H\]GTP, tritium-labeled GTP; \[γ^32^P\]GTP, gamma 32-phosphate-labeled GTP.

^b^ RAS binding (RB) and RAS association (RA) of various effectors were used; CRFA-N275 contains the N-terminal 275 aa encompassing RB domain; RALGDS-C127 contains the C-terminal 127 aa encompassing RA domain. PI3Kγ-RB consists of aa 144--1102.

^c^ BBA, bead--based assay; CPA, co-precipitation assay; FK, fluorescence kinetics; FP, fluorescence polarization; GDI, guanine nucleotide dissociation inhibition; ITC, isothermal titration calorimetry; SPA, scintillation proximity assay; SPR, surface plasmon resonance.

Materials and Methods {#sec002}
=====================

Constructs {#sec003}
----------

Fragments of human genes encoding both RBs of CRAF (accession number P04049; amino acids or aa 51--131), PI3Kα (P42336; aa 169--301), and RAs of RALGDS (Q12967; aa 777--872), PLCε (Q9P212; aa 2130--2240), RASSF5 (Q8WWW0; aa 200--358) were cloned into pMal-c5X-His vector. Constructs for the expression of human HRAS, KRAS, NRAS, RRAS1 and RRAS2 isoforms were described previously \[[@pone.0167145.ref005]\].

Proteins {#sec004}
--------

All RAS and the effector proteins were expressed in *Escherichia coli* using the pGEX and pMAL-His expression systems and prepared using glutathione and Ni-NTA based affinity chromatography as described previously \[[@pone.0167145.ref018]\]. RAS-mGppNHp was prepared as described \[[@pone.0167145.ref018]\].

Fluorescence polarization {#sec005}
-------------------------

RAS-effector interaction was performed in 50 mM Tris/HCl pH 7.5, 100 mM NaCl, 5 mM MgCl~2~ and 3 mM dithiothreitol at 25°C using a Fluoromax 4 fluorimeter in polarization mode as described \[[@pone.0167145.ref018]\]. Increasing amounts of MBP-tagged effector proteins (0.05--100 μM) titrated to 1 μM RAS-mGppNHp resulted in an increase of polarization. Equilibrium dissociation constants (K~d~) were calculated by fitting the concentration dependent binding curve using a quadratic ligand binding equation.

Sequence and structural analysis {#sec006}
--------------------------------

Sequence alignments were performed with Bioedit program using the ClustalW algorithm \[[@pone.0167145.ref044]\]. Chimera was used to adjust sequence alignments with superimposed structures \[[@pone.0167145.ref045]\]. A python code was written to match sequence alignments with complex structures ([S1 Table](#pone.0167145.s001){ref-type="supplementary-material"}) and calculate intermolecular contacts in the form of an interaction matrix. The intermolecular contacts were defined as pairs residues with a distance ≤4.0 Å between effectors and RAS proteins in available complex structures in the protein data bank (<http://www.pdb.org>). Biopython modules \[[@pone.0167145.ref046]\] were also used to elucidate corresponding residues in all available complex structures. All structural representations were generated using PyMol viewer \[[@pone.0167145.ref047]\].

Results {#sec007}
=======

A general approach for quantitative study of RAS-effector interaction {#sec008}
---------------------------------------------------------------------

As previous studies focused mainly on HRAS interaction with effectors, there is a lack of information for other RAS proteins ([Table 1](#pone.0167145.t001){ref-type="table"}). Dissociation constants (K~d~ values) have been invaluable in providing insights into particular RAS-effector interactions. However, they have been obtained under various conditions using diverse experimental techniques (see [Table 1](#pone.0167145.t001){ref-type="table"}) and cannot be used as such for a comparative evaluation of the interaction of different RAS proteins with various effectors. For this reason, we set out to analyze the interaction of HRAS, KRAS, NRAS, RRAS1 and RRAS2, with five distinct RB- and RA-containing effectors ([Fig 1](#pone.0167145.g001){ref-type="fig"}) under the same conditions. Since the kinetic analysis using stopped-flow spectrofluorometric method was not applicable to all isolated effector proteins, we utilized the fluorescence polarization approach \[[@pone.0167145.ref048]\].

Therefore, we prepared both, the RAS proteins in complex with mant (m) GppNHp, a non-hydrolysable fluorescent GTP analog, and the effector proteins fused to maltose-binding protein (MBP, 42 kDa). We chose the MBP because it increases the molecular mass of small-sized RB or RA domains, leads to an amplified fluorescence signal ([Fig 2A](#pone.0167145.g002){ref-type="fig"}) and ensures a homogeneous monomeric form of the fusion proteins. GST-fusion protein in contrast yielded a mixture of dimeric and monomeric species (data not shown). Equilibrium titration experiments revealed sufficient signal changes upon binding and guaranteed comparable experimental conditions for all measurements. By taking advantages of this method, complexes formed between these two types of proteins provided distinct polarized signals ([Fig 2A](#pone.0167145.g002){ref-type="fig"} and [S1 Fig](#pone.0167145.s002){ref-type="supplementary-material"}) that enabled us to determine K~d~ values for RAS-effector interactions ([Table 2](#pone.0167145.t002){ref-type="table"}).

![Equilibrium dissociation constants for RAS-effector interaction determined Fluorescence polarization.\
(A) Fluorescence polarization experiments were conducted by titrating mGppNHp-bound, active forms of RAS proteins (1 μM, respectively) with increasing concentrations of the respective effector domains as MBP fusion proteins. Data of two representative experiments for the interaction of KRAS (upper panel) and RRAS2 (lower panel) with CRAF-RB and PI3Kα-RB, respectively, are shown. All other data are illustrated in [S1 Fig](#pone.0167145.s002){ref-type="supplementary-material"} (B) Evaluated equilibrium dissociation constants (K~d~) in μM shown as data points illustrate a significant difference in the binding properties of the effector proteins with both RAS and RRAS isoforms, respectively. A mean value of 0.94 ± 0.014 μM has been determined for the interaction between HRAS and CRAF to exemplify the reproducibility of this approach.](pone.0167145.g002){#pone.0167145.g002}

10.1371/journal.pone.0167145.t002

###### Dissociation constants (K~d~) in μM for the interaction between RAS proteins and effectors.

![](pone.0167145.t002){#pone.0167145.t002g}

  Effector domains[^a^](#t002fn001){ref-type="table-fn"}   HRAS    KRAS    NRAS    RRAS1   RRAS2
  -------------------------------------------------------- ------- ------- ------- ------- -------
  CRAF-RB                                                  0.094   0.142   0.048   2.29    4.09
  RASSF5-RA                                                0.238   0.421   0.442   11.5    10.00
  RALGDS-RA                                                2.50    1.39    2.84    9.71    5.78
  PLCε-RA2                                                 3.70    8.90    5.36    114.4   145.4
  PI3Kα-RB                                                 84.3    204.7   145.0   11.00   18.10

^a^ The effector domain were used in these fluorescence polarization measurement as MBP fusion.

The affinities determined for the interaction between RAS proteins and individual effector domains vary between 48 nM for the NRAS--CRAF interaction and 205 μM for the interaction between KRAS and PI3Kα ([Fig 2B](#pone.0167145.g002){ref-type="fig"}; [Table 2](#pone.0167145.t002){ref-type="table"}). In general, the tested RAS proteins can be nicely divided according to their affinities into two distinctive groups, the first comprising HRAS, KRAS, NRAS and the second the RRAS proteins. Highest affinities were obtained for CRAF, which were roughly 3--8 fold higher when compared to those for RASSF5, followed by RALGDS and PLCε with K~d~ values in the lower micromolar ranges ([Fig 2B](#pone.0167145.g002){ref-type="fig"}; [Table 2](#pone.0167145.t002){ref-type="table"}). In contrast, RRAS1 and RRAS2 have similar micromolar affinities for the effectors and, interestingly, also for PI3Kα but not for PLCε. Our data clearly support previous findings (see [Table 1](#pone.0167145.t001){ref-type="table"}) that isolated effector domains, such as RB or RA, represent functional units, capable of recognizing and tightly binding to RAS proteins. Exceptions are the low affinity of PLCε RA domain for the RRAS proteins and PI3Kα RB domain for HRAS, KRAS and NRAS.

Identification of hotspots within protein interfaces {#sec009}
----------------------------------------------------

To date eleven complex structures of RAS proteins and their effectors has been determined ([S1 Table](#pone.0167145.s001){ref-type="supplementary-material"}). Since some of them contain more than one complex in the unit cell, there were altogether sixteen complex structures available for the analysis. In order to map atomic interactions responsible for observed variable affinities, we have extracted information about interacting interface from all these complex structures and combined them with their sequence alignments ([S2](#pone.0167145.s003){ref-type="supplementary-material"} and [S3](#pone.0167145.s004){ref-type="supplementary-material"} Figs). Interestingly, effectors show low sequence similarity ([S2A Fig](#pone.0167145.s003){ref-type="supplementary-material"}), but their mode of interaction appears to be well conserved as can be seen after a superposition of the complex structures on the RAS structure ([Fig 3](#pone.0167145.g003){ref-type="fig"} and [S4 Fig](#pone.0167145.s005){ref-type="supplementary-material"}). However, some amino acids aligned according to the sequence were quite distant in the space. Therefore, we edited the sequence alignment to synchronize it with structural alignment ([S2A Fig](#pone.0167145.s003){ref-type="supplementary-material"}). Our python code finally took sequence alignments with PDB files of complex structures as inputs and calculated all interaction pairs in analyzed complex structures in the form of a matrix ([Fig 4A](#pone.0167145.g004){ref-type="fig"}).

![Superposition of all available RAS--effector complex structures.\
Nine structures of RAS-effector domain complexes, found in a PDB search, including HRAS-CRAF (PDB code: 4g0n, 4g3x, 3kud; red), HRAS-BYR2 (PDB code: 1k8r; yellow), RAP1A-CRAF (PDB code: 1gua; lime), KRAS-ARAF (PDB code: 2mse; magenta), HRAS-RALGDS (PDB code: 1lfd; cyan), HRAS-PI3K (PDB code: 1he8; green), HRAS-PLCε (PDB code: 2c5l; orange), HRAS-RASSF (PDB code: 3ddc; blue), HRAS-GRAB14 (PDB code: 4k81; brown), were overlaid in ribbon presentation. Additional properties outside the interaction interface (box) are indicated.](pone.0167145.g003){#pone.0167145.g003}

![RAS-effector interaction hotspots.\
(A) Interaction matrix of RAS isoforms and effector proteins. Interaction matrix is launched to demonstrate interaction residues in all available structures (see [Fig 3](#pone.0167145.g003){ref-type="fig"} and [S4 Fig](#pone.0167145.s005){ref-type="supplementary-material"}). Left and upper parts comprise the amino acid sequence alignments of the RAS proteins and the effector domains, respectively. Each element corresponds to a possible interaction of RAS (row; HRAS numbering) and effector (column; CRAF numbering) residues. As indicated, interaction matrix represents five main regions, which cover the main interacting interfaces. (B) The five main regions, comprising the main hotspot for the RAS-effector interaction, are highlighted as ribbon and surface representations in the corresponding colors for the structures of HRAS-PLCε (PDB code: 2C5L) and HRAS-CRAF (PDB code: 4G0N). Key amino acids which are highlighted by colored background in A are indicated on the structures as well.](pone.0167145.g004){#pone.0167145.g004}

Interaction matrix and binding regions {#sec010}
--------------------------------------

An interaction matrix relates, in a comprehensive manner, the interacting residues on both sides of complexes, with RAS isoforms as rows and effector proteins as columns ([Fig 4A](#pone.0167145.g004){ref-type="fig"}). All numbering in this study is based on HRAS and CRAF proteins. Each element of the matrix accounts for the number of contacts between corresponding residues in all analyzed structures. Residues, involved in at least one interaction, were considered to represent a general interaction interface between RAS proteins and their effectors. Interacting amino acids form continuous patches on both sides of the complexes. Particular modes of interactions between parts of these two patches correspond to regions in the interacting matrix. We identified five such distinct regions (denoted from R1 to R5) in the matrix which had the highest number of interactions. These are separately highlighted in [Fig 4](#pone.0167145.g004){ref-type="fig"}.

Most pronounced is R1, located in the middle of matrix. Inspection of the particular interactions corresponding to this region clearly shows an arrangement of intermolecular β-sheet interactions in an anti-parallel fashion ([Fig 4B](#pone.0167145.g004){ref-type="fig"}). As many of these contacts in R1 are mediated by main-chain/main-chain interactions, we divided each element of R1 in the matrix into four categories of interactions (main-chain--main-chain, main-chain--side-chain, side-chain--main-chain and side-chain--side-chain; [S5 Fig](#pone.0167145.s006){ref-type="supplementary-material"}). Main-chain--main-chain interactions typically involve hydrogen bonds between the N-H group and the carbonyl oxygen. We found three interaction hotspots in all RAS-effector complexes, which represent a central recognition site in R1. These amino acids are Glu-37, Asp-38 and Ser-39 from the RAS side and positions 66 to 69 from the effector side ([Fig 4A](#pone.0167145.g004){ref-type="fig"}, red box). However, side-chain interactions are also highly populated in these spots indicating that the nature of amino acids in R1 region also influences the RAS-effector association ([S5 Fig](#pone.0167145.s006){ref-type="supplementary-material"}).

Another distinct region is R2, which corresponds to the interactions between the residues 21 to 34 of RAS, including the N-terminal half of switch I, and an elongated loop containing an α helix (in the case of PLCε and PI3Kα) and two α helices covering positions 83 to 90 ([Fig 4](#pone.0167145.g004){ref-type="fig"}). However, the overall shape of corresponding amino acids as well as the spatial orientation of α-helical structures is very diverse ([Fig 4B](#pone.0167145.g004){ref-type="fig"}). These structural diversities not only cause widely dispersed interactions in R2, but are also responsible for the interactions in the frames of region R4. The capability of RB domains in R2 to interact also with the β-strand in switch I of RAS simultaneously involves the recognition region R1 and gives rise to the region R4 ([Fig 4B](#pone.0167145.g004){ref-type="fig"}; upper panel). On the other hand, the spatial position of the N-terminal residues of RA domains in R1 is similar to the position of the C-terminal residues RB domains in R2 resulting in the interactions established in the region R5. Remarkably, the interaction matrix gives the hints for a region R3 ([Fig 4](#pone.0167145.g004){ref-type="fig"}) that could not be defined as a general interaction patch from a direct pair-wise comparison of individual complex structures. This region comprises critical residues, including Ile-36, Glu-37 and Tyr-64 on the RAS side, and positions 57, 59 and 71 on effector side. R3 very likely determines the selectivity of RAS-effector interaction, especially because of sequence deviations at this region (Arg-41 and Tyr-64) when comparing HRAS, KRAS and NRAS with RRAS1, RRAS2, RRAS3. Strikingly, the binding affinities between these two groups of RAS subfamilies are indeed different.

Discussion {#sec011}
==========

Since the discovery of the first RAS effector \[[@pone.0167145.ref049],[@pone.0167145.ref050],[@pone.0167145.ref051],[@pone.0167145.ref052]\], inhibition of RAS signaling by blocking RAS-effector interactions has been an ever-evolving and challenging venture \[[@pone.0167145.ref053],[@pone.0167145.ref054],[@pone.0167145.ref055],[@pone.0167145.ref056]\]. Biochemical and biophysical studies providing insights into the interaction of the downstream effectors with RAS proteins and their variants established the basic principles for drug design and development \[[@pone.0167145.ref031],[@pone.0167145.ref043],[@pone.0167145.ref053],[@pone.0167145.ref057],[@pone.0167145.ref058]\]. There is, however, a quite significant gap in our understanding of how RAS proteins specifically bind to, and activate, their diverse effectors. Rigorous understanding of this RAS-effector interplay would require an investigation of larger fragments or full-length effector proteins that was so far been accomplished in only a few studies \[[@pone.0167145.ref036],[@pone.0167145.ref059],[@pone.0167145.ref060]\]. For several reasons, isolated effector domains have been used in the vast majority of biochemical and structural studies for the investigation of their interactions with RAS proteins, predominantly with HRAS ([Table 1](#pone.0167145.t001){ref-type="table"} and [S1 Table](#pone.0167145.s001){ref-type="supplementary-material"}). However, interaction characteristics obtained for the same proteins differ considerably. For example, K~d~ values for the interaction of HRAS-GTP with CRAF or RALGDS vary from 5 to 330 nM and 80 nM to 39 μM, respectively ([Table 1](#pone.0167145.t001){ref-type="table"}). Another major difference of more than two orders of magnitude was observed for the interaction between RRAS1 and CRAF. Such a large variation of K~d~ values (summarized in [Table 1](#pone.0167145.t001){ref-type="table"}), which in addition have been determined by different groups using different methods and experimental conditions, made a comprehensive analysis of sequence-structure-function relationships practically impossible. Thus, we have quantitatively analyzed the interaction between five effector domains and five RAS proteins, covering for the first time RRAS2, under the same conditions ([Table 2](#pone.0167145.t002){ref-type="table"}).

Our measurements reveal that the RAS isoforms (HRAS, KRAS and NRAS) behave similarly toward each effector but very differently as compared to RRAS isoforms (RRAS1 and RRAS2), in spite of their high sequence identity. A previous study has reported that RAS isoforms much more strongly activate the MAPK pathway *via* the RAF kinase as compared to RRAS isoforms \[[@pone.0167145.ref060]\]. These data are consistent with K~d~ values determined in this study for RAS (ranging 0.048 to 0.142 μM) and RRAS (2.29 to 4.09 μM) isoforms. Notably, RRAS isoforms bind, except for PLCε, similarly to all tested effector domains with an up to 4-fold difference in binding affinities compare to RAS isoforms. Interestingly, they significantly interacted with PI3Kα but not with PLCε ([Table 2](#pone.0167145.t002){ref-type="table"}), which is in agreement with the cell-based data reported previously \[[@pone.0167145.ref060]\].

In particular, the RAS isoforms, which exhibit high selectivity for CRAF followed by RASSF5, RALGDS and PLCε, appeared not to retain affinity for PI3Kα. It could be argued that the isolated RB domain of PI3Kα (consisting of the amino acids 169--301) may lack additional binding determinants, when compared to the 50-fold higher affinity obtained with the isolated RB domain of PI3Kγ (amino acids 144--1102) (Tables [1](#pone.0167145.t001){ref-type="table"} and [2](#pone.0167145.t002){ref-type="table"}) \[[@pone.0167145.ref036]\]. A recent cell-based study has shown that RB domain of PI3Kα (aa 127--314) is sufficient to bind to ERAS, a newly discovered member of the RAS family, but obviously not to HRAS \[[@pone.0167145.ref005],[@pone.0167145.ref061]\]. However, the immunoprecipitation studies have revealed the endogenous PI3K isoforms α and γ interact with almost same affinity with both ERAS and HRAS \[[@pone.0167145.ref005]\]. These data suggest that RB domain of PI3K is sufficient for a tight interaction with ERAS but clearly requires additional capacity to properly associate with HRAS. Sequence deviations in effector binding regions may be critical for determining the minimal binding regions of RAS/effectors. It is, therefore, hypothesized that ERAS and RRAS isoforms but not RAS isoforms efficiently interact with RB domain of PI3Ks and that RAS isoforms need a second binding region or alternatively a scaffold protein.

Considering the affinities of RAS isoforms compared to RRAS isoforms, these are very similar for both groups regardless of the effector protein. Correspondingly, the RAS isoforms have identical effector binding regions and RRAS isoforms, also including RRAS3, revealed a very high sequence identity in these regions ([S3 Fig](#pone.0167145.s004){ref-type="supplementary-material"}). Considering differences in affinities between them, residues outside the interacting interface may play a role in the association *via* indirect long-range interactions, electrostatic steering or allosteric modulation. However, direct interacting residues that differ between these two classes of proteins are most likely to be responsible for observed differences. Noteworthy, there are only two such amino acids in the region R3 with significant occurrence in the interaction at position 41 (Arg/Thr in RAS isoforms compared to RRAS isoforms) and 64 (Tyr/Phe). R41 in RAS isoforms interacts favorably with asparagine and aspartic acid in CRAF respectively RASSF5, most likely stabilizing the high affinity interactions with the effector proteins. These interactions appear to be much weaker if Arg-41 is replaced by a threonine in RRAS isoforms. This explains, thus, huge differences in K~d~ between the RAS isoforms and the RRAS isoforms. The same arginine does not make such favorable contact with RALGDS or PLCε, contributing to lower affinities. Its interaction with counter residues in PI3K is loose in all analyzed complexes corresponding to higher K~d~ values for this effector. Interaction at this spot may determine effector selectivity between these isoforms, as confirmed for ERAS that has a tryptophan (Trp-79) at the corresponding position of Arg-41 in HRAS and has exhibited a higher selectivity for PI3K than CRAF \[[@pone.0167145.ref061]\]. Another crucial hotspot at position 64 of the RAS proteins very likely also plays an important role in the interaction with effectors. In accordance with the interaction matrix, it is in the vicinity of residues at effector positions 57 and 71, respectively. The mode of interaction between these residues, however, is not pronounced as in the case of Arg-41. Substitution of Tyr-64 for Phenylalanine may have very diverse impacts on the binding affinity.

The RB and RA domains share higher sequence homologies if they are aligned individually. However, there is no common consensus sequence for RAS binding if they are aligned together, particularly in the RAS binding regions R1 to R5 ([S2 Fig](#pone.0167145.s003){ref-type="supplementary-material"}; see arrowheads). Previous studies dealing with the interaction of small GTPases with their regulators have shown that there are patches of identical or highly homologous hotspots on both sides of protein surfaces that interact with each other \[[@pone.0167145.ref062],[@pone.0167145.ref063],[@pone.0167145.ref064]\]. Such interaction is evolutionary conserved and responsible for the recognition of counter proteins. Our finding that there is no patch of identical amino acids in RAS effector proteins ([Fig 4](#pone.0167145.g004){ref-type="fig"} and [S2 Fig](#pone.0167145.s003){ref-type="supplementary-material"}) seemed to break this rule. However, intermolecular β-sheet interactions between RAS proteins and their effectors are conserved and seem to supply the role of such critical patch (or in this special case, a stretch) of homologous amino acid residues. The analysis of complex structures showed that these interactions, covered by the recognition region R1 in the interaction matrix, are prevalent and occur in almost all structures. A β-sheet homodimer interface has been recently reported for the structures of KRAS-GTP that overlaps the binding site of the effectors within R1 \[[@pone.0167145.ref065]\]. Therefore, we have analyzed the proximity of effector binding residues in different RAS isoforms in the same way as of residues involved in β-sheet interactions and summarized the results as matrices ([Fig 4A](#pone.0167145.g004){ref-type="fig"} and [S5 Fig](#pone.0167145.s006){ref-type="supplementary-material"}). Introduction of four different interaction types in the matrix with high scores that separated main-chain and side-chain RAS-effector interactions allowed a detailed inspection of the central R1 region. Strikingly, there are three hotspots, which largely undergo main-chain/main-chain interactions (Glu-37 of RAS proteins with effector residues at position 68 and 69, respectively Asp-38 with residues at position 67; [S5 Fig](#pone.0167145.s006){ref-type="supplementary-material"}). These observations confirm the central role of R1 in the association of RAS proteins with their effectors and strongly suggest that the main-chain/main-chain interactions within this region are crucial for the recognition of these classes of proteins. Finally, we note that interactions in R1 also dependent, to a certain extent, on side chains of accompanying amino acids. They indirectly support the formation of β-sheet on both sides of complexes. However, they also utilize their side chains in another intramolecular interactions significantly contributing to the complex formation. In this way, Asp-38 interacts *via* its side chain exclusively with the effector residues at positions 68 and 69 within R1. Side chains of Glu-37 and Ile-37 undergo contacts with residues at positions 57 and 59 outside of the effector β-strand within the region R3. On the effector side of complexes, there are only two positions that contain identical or highly homologous amino acids, namely the position 59 and 84 ([Fig 4A](#pone.0167145.g004){ref-type="fig"}). In both cases they are populated by positively charged residues, with exception of PLCε that has a Gln at position 59. These residues interact with negatively charged residues on RAS proteins (Glu-37 and Asp-33) and strongly contribute to the formation of complexes. However, no unique and/or particular residue of effectors can be considered to cause the overall differences observed for their association with RAS proteins. Effector interacting residues are so variable at almost all interacting spots that only their concerted action is likely to explain the observed diversity.

Previous studies have shown that RAS variants (at residues Thr-35, Glu-37, Asp-38 and Tyr-40 and including also residues mentioned above) preferentially interact with some effectors but not others \[[@pone.0167145.ref039],[@pone.0167145.ref040],[@pone.0167145.ref041],[@pone.0167145.ref042]\]. However, to date there is no clear explanation for the variable selections of these mutants of RAS by specific effectors. The invariant Thr-35 of RAS was not located in one of the three main regions in the matrix as it is mainly involved in RAS structure and does not directly interact with RAF1. However, Spoerner and colleagues have shown that T35S mutation drastically reduces HRAS affinity for effectors, including CRAF-RB (60-fold) and RALGDS-RA (\>100-fold) \[[@pone.0167145.ref066]\]. They suggest that minor changes, such as truncating Thr-35 by a methyl group, strongly affect dynamic behavior of the switch 1 region and, in turn, its interaction with effectors. However, an early cell-based study has shown that HRAS T35S mutant interacts only with CRAF but not PI3K, BYR2, RALGDS or RASSF5, and activates the MAPK pathway \[[@pone.0167145.ref039]\]. One explanation may be that Gal1 scaffolds the HRAS^T35S^-CRAF \[[@pone.0167145.ref067]\]. On the other hand, the E37G mutation results in loss of PI3K and CRAF binding, but is able to interact with RA domain-containing effectors, such as RALGDS, RASSF5 and BYR2 \[[@pone.0167145.ref039]\]. Our interaction matrix shows contacts between E37G of HRAS and positively charged residues 61 and 69, and main-chain interactions with residue 69, and 70 of effectors. D38A mutation has been shown to retain CRAF binding but to lose interaction with PI3K, RALGDS and RASSF5 \[[@pone.0167145.ref042],[@pone.0167145.ref068]\]. Among different effector binding mutants, Y40C selectively activates PI3K but is unable to activate other effectors, such as RAF1, RALGDS, RASSF5 and BYR2 \[[@pone.0167145.ref069]\]. HRAS^G12V/Y40C^ and HRAS^G12V/E37G^ have been reported to cooperatively induce cell transformation *via* PI3K and RALGDS, respectively, but not *via* CRAF \[[@pone.0167145.ref040]\]. Vandal and colleagues have observed that KRAS^G12V/Y40C^-PI3K has the largest impact on an increase in tumor size whereas KRAS^G12V/E38G^-CRAF resulted in a decrease in tumor size but an increase of the number of tumors when combined with BRAF^V600E^ \[[@pone.0167145.ref070]\]. Being central elements of R1, R3 and R4, our analysis not only confirms a prominent role of Glu-37, Asp-38 and Tyr-40 in effector binding but also gives hints for the mode of their interaction, which relies on the main-chain-main-chain interaction. As this interaction is largely independent of associated side chains, it can be considered as conserved in effectors. Consequently, it supplies the role of homologous residues found to be essential for the recognition of regulator proteins by Rho GTPases. Hence, we state that these RAS residues are responsible with their main-chain atoms for the recognition of effectors. On the other hand, side chains of these residues are still influential on the binding with effectors, either indirectly by affecting the structure of RAS switch I or directly by interacting with effector residues within the regions R3 and R4 of our interaction matrix.

In conclusion, our data collectively support previous observations that the specificity in the signaling properties and biological functions of the various RAS proteins arises from the specific combination of effector pathways they regulate in each cell type. Considering the identity of interacting residues of different types of isoforms, a uniform association of RAS isoforms or rather RRAS isoforms can be expected with a particular effector. This raises the questions of how does the cell selects between respective RAS proteins and maintains respective effector activation. There are several review articles illustrating the current state of the art regarding the activation mechanism of various effectors \[[@pone.0167145.ref009],[@pone.0167145.ref011],[@pone.0167145.ref012],[@pone.0167145.ref013],[@pone.0167145.ref021],[@pone.0167145.ref071],[@pone.0167145.ref072],[@pone.0167145.ref073]\]. HRAS, KRAS and NRAS exhibit remarkable differences beyond their common interaction interfaces for regulators and effectors \[[@pone.0167145.ref074],[@pone.0167145.ref075],[@pone.0167145.ref076]\], especially at their C-terminal hypervariable region ([S3 Fig](#pone.0167145.s004){ref-type="supplementary-material"}), which has different features, including protein-protein interaction \[[@pone.0167145.ref077],[@pone.0167145.ref078]\]. An interesting issue, which is increasingly appreciated, is a RAS-membrane interaction that appears to generate RAS isoform specificity with respect to effector interactions \[[@pone.0167145.ref079],[@pone.0167145.ref080],[@pone.0167145.ref081]\]. This is likely achieved by RAS-specific scaffold proteins, including CaM, GAL1, GAL3, IQGAPs, NPM1, NCL, SHOC2/SUR8 \[[@pone.0167145.ref078],[@pone.0167145.ref082]\], which may modulate isoform specificity at specific site of the cell. Hence, elucidation of the RAS signal transduction requires not only RAS-effector interactions but also additional structures and interplay of multiprotein complexes \[[@pone.0167145.ref025]\]. Another critical aspect is sorting/trafficking of the isoforms \[[@pone.0167145.ref083],[@pone.0167145.ref084]\] that has recently been shown to be highly specific for the respective RAS proteins and dependents on specific posttranslational modifications, including prenylation and acylation \[[@pone.0167145.ref085],[@pone.0167145.ref086]\], phosphorylation \[[@pone.0167145.ref087],[@pone.0167145.ref088]\], ubiquitination \[[@pone.0167145.ref089],[@pone.0167145.ref090],[@pone.0167145.ref091],[@pone.0167145.ref092]\] and acetylation \[[@pone.0167145.ref093],[@pone.0167145.ref094],[@pone.0167145.ref095]\]. Similar characteristics have been reported for the RRAS isoforms, including protein-protein interaction required for subcellular localization, e.g., at focal adhesion or recycling endosomes,\[[@pone.0167145.ref096],[@pone.0167145.ref097]\], and posttranslational modifications \[[@pone.0167145.ref098],[@pone.0167145.ref099],[@pone.0167145.ref100]\]. In addition, they contain extended N-termini ([S3 Fig](#pone.0167145.s004){ref-type="supplementary-material"}) that have been shown to be critical for RRAS1 in cell migration \[[@pone.0167145.ref101]\]. The N-terminus of ERAS, which undergoes multiple interaction with other proteins (Nakhaeizadeh *et al*., unpublished), contains (like RRAS1) putative SH3-binding motifs. These motifs may provide additional mechanisms for sorting and trafficking to specific subcellular sites.

An issue, that remained to be elucidated in more detail, is the mechanism of effector activation. Notably, identification of additional components of the RAS signal transduction is a critical step towards understanding the relationship between the RAS proteins and the selective activation of respective effectors. Functional reconstitution of RAS interaction networks by using appropriate liposomes and full-length effector proteins may eventually provide fundamental insights into the functional characterization of multiprotein complexes of RAS and the complete identification of regulatory mechanisms.
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###### Published structures of the RAS and Effector protein complexes.
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Click here for additional data file.

###### Equilibrium dissociation constants for RAS-effector interaction.

Fluorescence polarization experiments were conducted to determine the dissociation constants (K~d~) by titrating mGppNHp-bound, active forms of RAS proteins (1 μM, respectively) with increasing concentrations of the respective effector domains, as indicated. The y-axis represents fluorescence polarization and the x-axis the concentration of the effector domain as MBP fusion proteins in μM. Evaluated equilibrium K~d~ values are illustrated as bar charts in [Fig 2](#pone.0167145.g002){ref-type="fig"} and summarized in [Table 2](#pone.0167145.t002){ref-type="table"}.
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###### Sequence Alignment of the RAS effector domains.

The overall amino acid alignment of RB and RA domains (A) was adjusted with structure alignment to increase the identity score. The latter was clearly increased when we separated RB domains of RAF isoforms (B) and the catalytic subunits of PI3K isoforms (C) from the RA domains (D). The five regions, described in [Fig 3](#pone.0167145.g003){ref-type="fig"}, are highlighted as arrowheads: R1 in red, R2 in green, R3 in blue, R4 in orange and R5 in purple. The secondary structure elements, the α helices and β sheets, from the RA domains were deduced from the crystal structures of HRAS complexes with RALGDS (PDB code: 1LFD) \[[@pone.0167145.ref037]\], RASSF5 (PDB code: 3DDC) \[[@pone.0167145.ref117]\], PLCε (PDB code: 2C5L) \[[@pone.0167145.ref034]\], and GRB14 (PDB code: 4K81) \[[@pone.0167145.ref118]\], respectively.
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###### Overall sequence comparison of human RAS proteins.

Multiple amino acid sequence alignment of RAS proteins with high similarities has been determined by ClustalW. Interaction regions, R1 to R5, at interface with the RB and RA effector domains are illustrated by arrowhead (color-coding is the same as in [Fig 4](#pone.0167145.g004){ref-type="fig"}: R1 in red; R2 in green; R3 in blue; R4 in purple; R4 in orange). The secondary structure elements, the α helices and β sheets, of the G domain were deduced from the HRAS crystal structure (PDB code: 5P21) \[[@pone.0167145.ref119]\]. G1 to G5 boxes indicate the presence of five essential GDP/GTP binding (G) motifs. The three amino acid deviations between RAS and RRAS isoforms that are critical selectivity-determining residues for effector binding are highlighted in red.
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###### Known structures of the RAS-effector complexes.

Nine structures of RAS-effector domain complexes were found in a PDB search, including HRAS-CRAF-RB (PDB code: 4g0n, 4G3X, 3kud), HRAS-BYR2-RB (PDB code: 1k8r), RAP1A-CRAF-RB (PDB code: 1GUA), KRAS-ARAF-RB (PDB code: 2mse), HRAS-RALGDS (PDB code: 1lfd), HRAS-PI3Kγ (PDB code: 1he8), HRAS-PLCε (PDB code: 2c5l), HRAS-RASSF (PDB code: 3ddc), HRAS-GRAB14 (PDB code: 4k81). An overlaid structure in ribbon presentation (central panel) illustrates the overall contacts of these structures (see also [Fig 3](#pone.0167145.g003){ref-type="fig"}). The contact sites (with distances of 4 Å or less) were calculated by Pymol and colored in white. RAS proteins are shown in orchid and the effector domains in olive as indicated.
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###### Intermolecular β sheet-β sheet interactions covered by the recognition region R1.

Intermolecular β sheet interactions between RAS proteins and their effectors is covered by the recognition region R1 in the interaction matrix, which is launched to demonstrate interaction residues in all available structures. Left and upper panels comprises the amino acid sequence alignment of RAS and effector proteins, respectively. Each element corresponds a possible interaction of RAS (row) and effectors (column) residues. Besides, each element involves four sub-elements, which show a combination of main-chain and side-chain interactions, as indicated. Main-chain--main-chain contacts are shown in red.
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